Clovis Oncology: A Classic Story Of Value Disconnect

|
About: Clovis Oncology, Inc. (CLVS)
by: BioSci Capital Partners
This article is exclusive for subscribers.
Summary

Facing drug pricing control and China Trade War, Clovis shares are being clobbered. Nonetheless, the fundamentals are strong.

Rubraca sales for ovarian cancer steadily increase and thereby represent a drug that garners strong sales tractions.

Nonetheless, I'm most interested in Rubraca's development for patients suffering from metastatic castration-resistant prostate cancer with an associated BRCA1/2 mutation.

Management must be willing to submit itself to the disciplines required for sound growth. - Phillip Fisher

In the thick of concerns relating to drug pricing control and China Trade War, Clovis Oncology (NASDAQ:CLVS